QDEM PHARMACEUTICALS LIMITED
ActiveKey figures
† QDEM PHARMACEUTICALS LIMITED filed these accounts on paper, so Companies House publishes them only as a scanned image. The figures for the years marked † were read automatically from the scan and kept only where the statements add up (for example net assets equal total equity), but a reading error is still possible — check the original accounts at Companies House.
Ratios
2025Sector comparison
SIC 46460Where the company stands among the 2,974 active companies whose first SIC code is 46460 (Wholesale of pharmaceutical goods).
- CSL BEHRING HOLDINGS LIMITED£11bn
- VIIV HEALTHCARE UK LIMITED£5.7bn
- MCKESSON GLOBAL SOURCING LIMITED£1bn
- MCKESSON MEDICAL-SURGICAL SOURCING LIMITED£999.5m
- PFIZER LIMITED£984m
- ABBOTT LABORATORIES LIMITED£871.8m
- GLAXOSMITHKLINE UK LIMITED£779m
- UNIKERIS LIMITED£642m
- HALEON UK TRADING LIMITED£554.8m
- MUNDIPHARMA MEDICAL COMPANY LIMITED£461.7m
Positions are approximate. Figures come from each company's latest accounts; money and employee figures are compared only with companies that filed accounts in pounds for a period ending in the last two and a half years and are not dormant, so those groups are smaller than 2,974. The line on each bar marks the median.
Summary: QDEM PHARMACEUTICALS LIMITED
What kind of company is it?
QDEM PHARMACEUTICALS LIMITED is a private limited company registered with Companies House under company number 07841452. It was incorporated on 9 Nov 2011. Its status is active. The registered office is in Cambridge (CB4). Its nature of business (SIC 2007) is wholesale of pharmaceutical goods (46460).
How is the company doing financially?
The latest accounts in the database are for 2025 (period ending 31 Dec 2025); the company files full accounts. Turnover was £27,858,000. Profit for the year was £627,000. Net assets were £6,454,000, up 10.8% on the previous year. Total assets were £7,609,000 and total liabilities £1,155,000. Figures are available for 2 financial years (2024–2025).
How does it compare with similar companies?
Compared with 2,974 active companies whose first SIC code is 46460: By turnover it ranks higher than 55% of the 214 that publish turnover (median £23,764,000). By net assets it ranks higher than 90% of them (median £32,520). By total assets it ranks higher than 84% of them (median £255,000). It is older than 75% of them (median age 6.2 years).
Does it supply the public sector?
The company is named as a supplier in 6 public contract award notices from 3 public sector buyers since 2020. Contracts awarded to it alone have a combined published value of £95.2m. Its most frequent buyer is NHS England (4 contracts). 3 of the awards are shared with other suppliers, typically framework agreements.
Who runs and controls the company?
One person with significant control is registered.
When are its next filings due?
The next accounts are due by 30 Sep 2027. The next confirmation statement is due by 12 Jun 2027.
Filed accounts2024–2025
| 2024 † | 2025 † | |
|---|---|---|
| Turnover | 30,311,000 | 27,858,000 |
| Profit for the year | 682,000 | 627,000 |
| Cash at bank and in hand | 3,000 | — |
| Total assets | 10,411,000 | 7,609,000 |
| Total liabilities | 4,584,000 | 1,155,000 |
| Net assets / total equity | 5,827,000 | 6,454,000 |
A dash (—) means no accounts were filed for that year or the item is not in the accounts; 0 is a zero stated in the accounts. Small companies usually file only a balance sheet, so the profit and loss account is often missing.
Public contracts
6 contractsQDEM PHARMACEUTICALS LIMITED is named as a supplier in 6 public contract award notices from 3 public sector buyers since 2020. The 1 contract awarded to it alone with a published value add up to £95.2m. 3 awards are shared with other suppliers and not counted in that total.
- NHS England
- 4 contracts · £95.2m
- The Common Services Agency (more commonly known as NHS National Services Scotland) ("the…
- 1 contract
- The NHS Commissioning Board (operating under the name of NHS England)
- 1 contract
- NP40925 Analgesics, Anaesthetics, Musculoskeletal & Joint Disease Medicines‡The Common Services Agency (more commonly known as NHS National Services Scotland) ("the… · shared by 7 suppliers, up to £267,570 in total · 2 lots
- NHS Framework Agreement-Branded Medicines - National Proprietary Pharmaceuticals‡NHS England · shared by 50 suppliers, up to £304,504,000 in total
- NHS Framework Agreement for Branded Medicines - National Proprietary Pharmaceuticals‡NHS England · £1
- NHS Framework Agreement for Branded Medicines – National‡NHS England · £95,224,871
- NHS National Generic Pharmaceuticals Interim 2‡NHS England · shared by 51 suppliers, up to £12,327,097 in total
Show 1 more
- NHS National Generic Pharmaceuticals Interim 2 2020‡The NHS Commissioning Board (operating under the name of NHS England) · £1
From contract award notices on Contracts Finder (since 2016) and Find a Tender (since 2021), published by the Cabinet Office under the Open Government Licence v3.0. Values are as published by the buyer and usually cover the whole contract term; the total leaves out awards shared between several suppliers, where the published figure is a ceiling for all of them, placeholder values and single figures of £1 billion or more. Notices marked ‡ do not state a company number and were linked by an exact match on the registered name. Contracts below the publication thresholds and those of devolved buyers that publish elsewhere are not included.
History
4 events- Financial year 2025 endedAccounts: turnover £27.9m, net assets £6.5m
- Financial year 2024 endedAccounts: turnover £30.3m, net assets £5.8m
- Napp Pharmaceutical Holdings Limited registered as a person with significant control
- Company incorporatedPrivate limited company
Dates as recorded at Companies House: incorporation, name changes, officer appointments and resignations, current persons with significant control, and the end of each financial year with figures in the database. Former persons with significant control are not listed.